SJ
Shenzhen JYMed Technology Co., Ltd. (JYMed Peptide)
CDMO · Shenzhen, China
GMP
Overview
JYMed Peptide was founded in 2009 and focuses on peptide development and manufacturing, with about 650 staff, 13 cGMP production lines and 85,000 L of SPPS/LPPS reactor volume. It offers custom synthesis, CDMO services, commercial peptide APIs and cosmetic and veterinary peptides. It holds active US Type II DMFs for Degarelix, Liraglutide, Oxytocin, Semaglutide, Teriparatide, Tirzepatide. Its website states its sites are approved by FDA, NMPA and EDQM.
Capabilities
- Peptide CDMO
- Commercial peptide APIs
- Custom synthesis mg to ton
- Peptide modification and conjugates
- Injectable formulation site
Quality signals
| GMP evidence | Yes |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |